Cytokinetics, Incorporated
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CYTK research report →
Range $81 – $118
Price Chart
About the company
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction.
- CEO
- Robert I. Blum
- IPO
- 2004
- Employees
- 673
- HQ
- South San Francisco, CA, US
Get TickerSpark's AI analysis on CYTK
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $7.07B
- P/E
- -8.53
- Fwd P/E
- 48.13
- PEG
- -8.43
- P/S
- 63.28
- P/B
- -22.28
- EV/EBITDA
- -11.89
- Div Yield
- 0.00%
- Gross Margin
- 91.00%
- Op Margin
- -625.15%
- Net Margin
- -686.63%
- ROE
- 157.08%
- ROIC
- -42.48%
Latest fiscal year · YoY change
- Revenue
- $88.04M+376.6%
- Gross Profit
- $77.91M+124.3%
- Op Income
- $-612,258,000
- Net Income
- $-784,955,000-33.2%
- EPS
- $-6.54-24.3%
- OCF Growth
- -28.8%
- FCF Growth
- -33.8%
- 52W High
- $88.31
- 52W Low
- $50.32
- 50D MA
- $62.35
- 200D MA
- $69.53
- Beta
- 0.36
- RSI (14)
- 31
- Avg Volume
- 2.02M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Cytokinetics posted a strong Q3 as MYQORZO launch momentum accelerated, while the company advanced its aficamten expansion into nonobstructive HCM and reaffirmed full-year spending guidance.· November 4, 2026
- MYQORZO net revenue was $44.5 million in Q3, up 76% sequentially, with U.S. sales of $43.1 million.
- Total revenue was $47.6 million versus $1.9 million a year ago; net loss was $190.1 million, or $1.37 per share, versus $306.2 million, or $2.55 per share.
- Commercial metrics improved sharply: nearly 1,100 U.S. prescribers, more than 2,800 patients dispensed, over 60% commercial lives covered, and paid prescriptions above 80%.
- Aficamten in nHCM remains on track for an FDA sNDA submission this quarter, with an EMA filing planned for early 2027.
- Management reiterated full-year 2026 GAAP combined R&D and SG&A guidance of $860 million to $890 million and stock comp of $130 million to $140 million.
Total revenues were $47.6 million in Q3 2026, compared with $1.9 million in Q3 2025. MYQORZO net product revenue was $44.5 million, up 76% quarter-over-quarter; U.S. net product revenue was $43.1 million and Europe contributed $1.4 million, mainly from initial inventory build in Germany. Collaboration revenue was $3.1 million versus $1.9 million a year ago. R&D expense was $99.3 million versus $97.3 million last year, SG&A was $113.1 million versus $69.5 million, and net loss was $190.1 million, or $1.37 per share, versus $306.2 million, or $2.55 per share. The company ended the quarter with approximately $1.6 billion in cash and investments, down from $1.7 billion at the end of Q2 2026. Management reaffirmed full-year 2026 GAAP combined R&D and SG&A guidance of $860 million to $890 million, with stock-based compensation unchanged at $130 million to $140 million.
Robert Blum framed the quarter as another period of strong execution toward Cytokinetics’ goal of becoming a leading muscle-focused specialty cardiology company. He highlighted that MYQORZO continues to outperform expectations, Germany is off to a strong start, and the company is on track for a nHCM sNDA submission this quarter. His tone was confident and forward-looking, emphasizing a broad commercial and regulatory roadmap through 2027 while staying disciplined on capital deployment.
Sung Lee focused on the quarter’s financial buildout and spending discipline. He cited $47.6 million of total revenue, $44.5 million of MYQORZO net product revenue, a $99.3 million R&D run rate, and $113.1 million of SG&A tied largely to launch and personnel costs. He also noted MYQORZO cost of goods sold was a $0.5 million credit due to supply optimization and that the company finished with approximately $1.6 billion in cash and investments. Importantly, he reaffirmed full-year 2026 GAAP combined R&D and SG&A guidance of $860 million to $890 million, including $130 million to $140 million of stock-based compensation.
Analysts focused heavily on how sustainable the category growth is, whether the company could eventually move to a less burdensome REMS/titration paradigm, and what the size and timing of the Europe and nHCM opportunities might be. Management said category growth is still being driven by prescriber expansion, estimated around 3,000-plus patients per quarter, and that a real-world evidence base over 2 to 3 years could support REMS simplification. On Europe, they said the mature market could eventually be about 15% of MYQORZO revenue, with more meaningful contribution in 2028-2029. On nHCM, they said existing MYQORZO writers should adopt faster because they already know the drug, the REMS, and the titration process.
The bull case is that MYQORZO appears to be gaining real commercial traction quickly, with prescriber breadth, patient volume, access, and share all moving in the right direction. Management also sounded increasingly confident that aficamten could expand into nHCM, potentially opening a larger market and strengthening the brand across the full HCM spectrum.
The main risks are that the launch is still early, Europe will likely ramp slowly, and the company still faces regulatory execution risk around MAPLE-HCM, the nHCM sNDA, and future REMS discussions. Analysts also pressed on whether growth can keep scaling without prescriber expansion, and management acknowledged that a broader inflection may take time and that some of the biggest changes depend on future data and approvals.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 96.5%
- Shares Outstanding
- 139.30M
- Float Shares
- 134.42M
of shares held by institutions
515 13F filers
Buy/sell ratio 0.65. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for CYTK, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 21.04M | ▲ 946.79K |
| T. Rowe Price Investment Management, Inc. | 18.72M | ▲ 1.19M |
| Vanguard Group Inc | 12.05M | ▲ 191.34K |
| State Street Corp | 7.14M | ▲ 649.00K |
| Wellington Management Group Llp | 6.93M | ▼ 1.08M |
| Vanguard Portfolio Management LLC | 6.80M | ▲ 87.74K |
| Vanguard Capital Management LLC | 6.27M | ▲ 148.90K |
| Avoro Capital Advisors LLC | 5.00M | ▲ 1.67M |
| Bank Of America Corp | 4.64M | ▲ 1.51M |
| Geode Capital Management, LLC | 3.77M | ▲ 55.36K |
| Invesco Ltd. | 3.02M | ▲ 1.78M |
| Rtw Investments, LP | 2.86M | ▲ 140.84K |
Held by 478 ETFs
Biggest fund positions in CYTK by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | Blum Robert I | other | 7,500 |
| Nov 16, 26 | Blum Robert I | sell | 5,077 |
| Nov 16, 26 | Blum Robert I | sell | 2,223 |
| Nov 16, 26 | Blum Robert I | sell | 200 |
| Nov 16, 26 | Blum Robert I | other | 7,500 |
| Nov 17, 26 | Malik Fady Ibraham | other | 3,500 |
| Nov 17, 26 | Malik Fady Ibraham | sell | 3,300 |
| Nov 17, 26 | Malik Fady Ibraham | sell | 200 |
| Nov 17, 26 | Malik Fady Ibraham | other | 3,500 |
| Nov 17, 26 | Hessekiel Jeffrey | sell | 15,106 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CYTK coverage
Recent articles, reports, and earnings notes.
Want a deeper read on CYTK?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Cytokinetics Touts MYQORZO Launch Momentum, Plans New FDA Filing
marketbeat.com · Nov 17
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Nov 16
Cytokinetics, Incorporated (CYTK) Presents at UBS Global Biopharma Conference 2026 Transcript
seekingalpha.com · Nov 16
Cytokinetics Announces Prescribing Information for MYQORZO® (aficamten) Expanded to Include Data from Phase 3 MAPLE-HCM
globenewswire.com · Nov 16
Cytokinetics' MYQORZO Gains Ground as Company Plans Push Into New Heart-Disease Market
marketbeat.com · Nov 16
Cytokinetics Announces Additional Data Related to Aficamten Presented at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026
globenewswire.com · Nov 9
Cytokinetics, Incorporated (CYTK) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 4
Cytokinetics Q3 Earnings Call Highlights
marketbeat.com · Nov 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
